Drug Profile
Research programme: cancer and inflammatory disorder therapeutics - Coegin Pharma
Alternative Names: AVX 002; AVX 003; AVX 235; AVX 440; AVX 449Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Avexxin
- Developer Coegin Pharma
- Class Small molecules
- Mechanism of Action Immunomodulators; Phospholipase A2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Glomerulonephritis; Rheumatoid arthritis
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in Norway
- 01 Oct 2019 Avexxin is now called Coegin Pharma
- 04 Nov 2017 No recent reports of development identified for preclinical development in Glomerulonephritis in Norway